RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000077.xml
PDF herunterladen
Semin Thromb Hemost 2019; 45(05): 468-477
DOI: 10.1055/s-0039-1692702
DOI: 10.1055/s-0039-1692702
Review Article
Cardiac Manifestations of Antiphospholipid Syndrome: Clinical Presentation, Role of Cardiac Imaging, and Treatment Strategies
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
19. Juni 2019 (online)
Abstract
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence of antiphospholipid antibodies, vascular thrombosis (venous, arterial, or small vessels), and/or pregnancy morbidity. Diagnosis of APS is based on the presence of at least one clinical criterion (thrombotic events or pregnancy morbidity) and at least one of the laboratory criteria (persistently medium/high titer immunoglobulin G [IgG]/immunoglobulin M [IgM] anticardiolipin antibodies, and/or medium/high titer IgG/IgM anti-β2-glycoprotein I antibodies, and/or a positive lupus anticoagulant test), confirmed after repetition at least 12 weeks apart. The clinical spectrum of APS encompasses additional (extracriteria) clinical manifestations, including cardiac diseases. Heart involvement may become evident as a consequence of direct (autoimmune-mediated) or indirect (thrombosis) mechanisms, and include valve heart disease (vegetations and/or thickening associated with functional abnormalities) and intracardiac thrombosis, coronary, and vascular accelerated atherosclerosis, along with ischemic heart disease. APS can also cause pulmonary arterial hypertension, left ventricular dysfunction, and heart failure. This review describes the major cardiac manifestations of APS and illustrates the role of cardiac imaging for diagnosing subclinical and overt heart involvement and addressing management of these patients. The possible role of therapeutic strategies in cardiac manifestations of APS is also discussed.
-
References
- 1 George D, Erkan D. Antiphospholipid syndrome. Prog Cardiovasc Dis 2009; 52 (02) 115-125
- 2 Wilson WA, Gharavi AE, Koike T. , et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42 (07) 1309-1311
- 3 Miyakis S, Lockshin MD, Atsumi T. , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
- 4 Pengo V, Bison E, Denas G, Jose SP, Zoppellaro G, Banzato A. Laboratory diagnostics of antiphospholipid syndrome. Semin Thromb Hemost 2018; 44 (05) 439-444
- 5 Devreese KM, Pierangeli SS, de Laat B, Tripodi A, Atsumi T, Ortel TL. ; Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost 2014; 12 (05) 792-795
- 6 Di Minno MN, Tufano A, Ageno W, Prandoni P, Di Minno G. Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. Intern Emerg Med 2012; 7 (01) 9-13
- 7 Cervera R, Piette JC, Font J. , et al; Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46 (04) 1019-1027
- 8 Martini A, Ravelli A. The clinical significance of antiphospholipid antibodies. Ann Med 1997; 29 (02) 159-163
- 9 Tufano A, Guida A, Di Minno MN, De Gregorio AM, Cerbone AM, Di Minno G. Cardiovascular events in patients with antiphospholipid antibodies: strategies of prevention. Nutr Metab Cardiovasc Dis 2010; 20 (04) 217-223
- 10 Gómez-Puerta JA, Cervera R. Diagnosis and classification of the antiphospholipid syndrome. J Autoimmun 2014; 48-49: 20-25
- 11 Espinosa G, Cervera R. Current treatment of antiphospholipid syndrome: lights and shadows. Nat Rev Rheumatol 2015; 11 (10) 586-596
- 12 Zuily S, Huttin O, Mohamed S, Marie PY, Selton-Suty C, Wahl D. Valvular heart disease in antiphospholipid syndrome. Curr Rheumatol Rep 2013; 15 (04) 320
- 13 Abreu MM, Danowski A, Wahl DG. , et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev 2015; 14 (05) 401-414
- 14 Sciascia S, Amigo MC, Roccatello D, Khamashta M. Diagnosing antiphospholipid syndrome: ‘extra-criteria’ manifestations and technical advances. Nat Rev Rheumatol 2017; 13 (09) 548-560
- 15 Sacharidou A, Shaul PW, Mineo C. New insights in the pathophysiology of antiphospholipid syndrome. Semin Thromb Hemost 2018; 44 (05) 475-482
- 16 Tufano A, Guida A, Cerbone AM, Di Minno G. The “antiphospholipid triangle” in an asymptomatic patient: a case report. Intern Emerg Med 2010; 5 (05) 457-458
- 17 Denas G, Jose SP, Bracco A, Zoppellaro G, Pengo V. Antiphospholipid syndrome and the heart: a case series and literature review. Autoimmun Rev 2015; 14 (03) 214-222
- 18 Tenedios F, Erkan D, Lockshin MD. Cardiac manifestations in the antiphospholipid syndrome. Rheum Dis Clin North Am 2006; 32 (03) 491-507
- 19 Generali E, Folci M, Selmi C, Riboldi P. Immune-mediated heart disease. Adv Exp Med Biol 2017; 1003: 145-171
- 20 Mohammed AG, Alghamdi AA, ALjahlan MA, Al-Homood IA. Echocardiographic findings in asymptomatic systemic lupus erythematosus patients. Clin Rheumatol 2017; 36 (03) 563-568
- 21 Hojnik M, George J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 1996; 93 (08) 1579-1587
- 22 García-Torres R, Amigo MC, de la Rosa A, Morón A, Reyes PA. Valvular heart disease in primary antiphospholipid syndrome (PAPS): clinical and morphological findings. Lupus 1996; 5 (01) 56-61
- 23 Brenner B, Blumenfeld Z, Markiewicz W, Reisner SA. Cardiac involvement in patients with primary antiphospholipid syndrome. J Am Coll Cardiol 1991; 18 (04) 931-936
- 24 Krause I, Lev S, Fraser A. , et al. Close association between valvular heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis 2005; 64 (10) 1490-1493
- 25 Erdogan D, Goren MT, Diz-Kucukkaya R, Inanc M. Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: a transesophageal echocardiographic study. Stroke 2005; 36 (03) 592-596
- 26 Cervera R, Font J, Paré C. , et al. Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients. Ann Rheum Dis 1992; 51 (02) 156-159
- 27 Watad A, Tiosano S, Grysman N. , et al. The association between systemic lupus erythematosus and valvular heart disease: an extensive data analysis. Eur J Clin Invest 2017; 47 (05) 366-371
- 28 Kampolis C, Tektonidou M, Moyssakis I, Tzelepis GE, Moutsopoulos H, Vlachoyiannopoulos PG. Evolution of cardiac dysfunction in patients with antiphospholipid antibodies and/or antiphospholipid syndrome: a 10-year follow-up study. Semin Arthritis Rheum 2014; 43 (04) 558-565
- 29 Silbiger JJ. The cardiac manifestations of antiphospholipid syndrome and their echocardiographic recognition. J Am Soc Echocardiogr 2009; 22 (10) 1100-1108 , quiz 1195
- 30 Zavaleta NE, Montes RM, Soto ME, Vanzzini NA, Amigo MC. Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic follow-up study. J Rheumatol 2004; 31 (12) 2402-2407
- 31 Abanador-Kamper N, Wolfertz J, Kamper L, Haage P, Seyfarth M. Disseminated intracardiac thrombosis: a rare manifestation of antiphospholipid syndrome. Eur Heart J Cardiovasc Imaging 2012; 13 (06) 537
- 32 Yuriditsky E, Torres J, Izmirly PM, Belmont HM. Resolution of large aortic valve vegetations in antiphospholipid syndrome treated with therapeutic anticoagulation: a report of two cases and literature review. Lupus 2018; 27 (14) 2269-2273
- 33 Urbanus RT. Recent developments in antiphospholipid antibodies and the antiphospholipid syndrome. Semin Thromb Hemost 2018; 44 (05) 417-418
- 34 Vaarala O, Mänttäri M, Manninen V. , et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91 (01) 23-27
- 35 Vaarala O. Antiphospholipid antibodies and myocardial infarction. Lupus 1998; 7 (Suppl. 02) S132-S134
- 36 Pons-Estel GJ, Andreoli L, Scanzi F, Cervera R, Tincani A. The antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun 2017; 76: 10-20
- 37 Cervera R. Antiphospholipid syndrome. Thromb Res 2017; 151 (Suppl. 01) S43-S47
- 38 Matsuura E, Lopez LR. Are oxidized LDL/beta2-glycoprotein I complexes pathogenic antigens in autoimmune-mediated atherosclerosis?. Clin Dev Immunol 2004; 11 (02) 103-111
- 39 Ames PR, Margarita A, Sokoll KB, Weston M, Brancaccio V. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis 2005; 64 (02) 315-317
- 40 Delgado Alves J, Mason LJ, Ames PR. , et al. Antiphospholipid antibodies are associated with enhanced oxidative stress, decreased plasma nitric oxide and paraoxonase activity in an experimental mouse model. Rheumatology (Oxford) 2005; 44 (10) 1238-1244
- 41 Cervera R. Coronary and valvular syndromes and antiphospholipid antibodies. Thromb Res 2004; 114 (5-6): 501-507
- 42 Escárcega RO, Lipinski MJ, García-Carrasco M, Mendoza-Pinto C, Galvez-Romero JL, Cervera R. Inflammation and atherosclerosis: cardiovascular evaluation in patients with autoimmune diseases. Autoimmun Rev 2018; 17 (07) 703-708
- 43 Danowski A, de Azevedo MN, de Souza Papi JA, Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 2009; 36 (06) 1195-1199
- 44 Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford) 2013; 52 (08) 1397-1403
- 45 Radin M, Schreiber K, Costanzo P. , et al. The adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction. Int J Cardiol 2017; 240: 72-77
- 46 Di Minno MND, Scalera A, Tufano A. , et al. The association of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) with cardiovascular disease in subjects with antiphospholipid antibodies. Atherosclerosis 2018; 278: 60-65
- 47 Negrini S, Pappalardo F, Murdaca G, Indiveri F, Puppo F. The antiphospholipid syndrome: from pathophysiology to treatment. Clin Exp Med 2017; 17 (03) 257-267
- 48 Sciascia S, Radin M, Bazzan M, Roccatello D. Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome. Intern Emerg Med 2017; 12 (01) 1-7
- 49 Espinola-Zavaleta N, Alexanderson-Rosas E, Granados N, Elena Soto M, Amigo MC. Myocardial perfusion defects in patients with autoimmune diseases: a prospective study. Analysis of two diagnostic tests. Lupus 2006; 15 (01) 38-43
- 50 Alexánderson E, Gómez-León A, Vargas A. , et al. Myocardial ischaemia in patients with primary APS: a 13N-ammonia PET assessment. Rheumatology (Oxford) 2008; 47 (06) 894-896
- 51 Alexanderson E, Cruz P, Vargas A. , et al. Endothelial dysfunction in patients with antiphospholipid syndrome assessed with positron emission tomography. J Nucl Cardiol 2007; 14 (04) 566-572
- 52 Ishimori ML, Martin R, Berman DS. , et al. Myocardial ischemia in the absence of obstructive coronary artery disease in systemic lupus erythematosus. JACC Cardiovasc Imaging 2011; 4 (01) 27-33
- 53 Sacré K, Brihaye B, Hyafil F. , et al. Asymptomatic myocardial ischemic disease in antiphospholipid syndrome: a controlled cardiac magnetic resonance imaging study. Arthritis Rheum 2010; 62 (07) 2093-2100
- 54 Gonçalves LF, Souto FM, Faro FN, Oliveira JL, Barreto-Filho JA, Sousa AC. Biventricular thrombus and endomyocardial fibrosis in antiphospholipid syndrome. Arq Bras Cardiol 2012; 99 (05) e162-e165
- 55 Gerede DM, Yüksel B, Tutar E. , et al. Spontaneous coronary artery dissection in a male patient with Takayasu's Arteritis and Antiphospholipid Antibody Syndrome. Case Rep Rheumatol 2013; 2013 (27) 272963
- 56 Paran D, Caspi D, Levartovsky D. , et al. Cardiac dysfunction in patients with systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis 2007; 66 (04) 506-510
- 57 Laskin CA, Clark CA, Spitzer KA. Antiphospholipid syndrome in systemic lupus erythematosus: is the whole greater than the sum of its parts?. Rheum Dis Clin North Am 2005; 31 (02) 255-272 , vi
- 58 Tektonidou MG, Ioannidis JP, Moyssakis I. , et al. Right ventricular diastolic dysfunction in patients with anticardiolipin antibodies and antiphospholipid syndrome. Ann Rheum Dis 2001; 60 (01) 43-48
- 59 Nihoyannopoulos P, Gomez PM, Joshi J, Loizou S, Walport MJ, Oakley CM. Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies. Circulation 1990; 82 (02) 369-375
- 60 Bidani AK, Roberts JL, Schwartz MM, Lewis EJ. Immunopathology of cardiac lesions in fatal systemic lupus erythematosus. Am J Med 1980; 69 (06) 849-858
- 61 Lauwerys BR, Lambert M, Vanoverschelde JL, Cosyns JP, Houssiau FA. Myocardial microangiopathy associated with antiphospholipid antibodies. Lupus 2001; 10 (02) 123-125
- 62 Azeem T, Vassallo M, Samani NJ. Images in cardiology. Endomyocardial fibrosis associated with antiphospholipid syndrome. Heart 2000; 84 (02) 156
- 63 Roman MJ, Salmon JE, Sobel R. , et al. Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am J Cardiol 2001; 87 (05) 663-666 , A11
- 64 Leung WH, Wong KL, Lau CP, Wong CK, Cheng CH, Tai YT. Doppler echocardiographic evaluation of left ventricular diastolic function in patients with systemic lupus erythematosus. Am Heart J 1990; 120 (01) 82-87
- 65 Giunta A, Picillo U, Maione S. , et al. Spectrum of cardiac involvement in systemic lupus erythematosus: echocardiographic, echo-Doppler observations and immunological investigation. Acta Cardiol 1993; 48 (02) 183-197
- 66 Hasnie AM, Stoddard MF, Gleason CB. , et al. Diastolic dysfunction is a feature of the antiphospholipid syndrome. Am Heart J 1995; 129 (05) 1009-1013
- 67 Coudray N, de Zuttere D, Blétry O. , et al. M mode and Doppler echocardiographic assessment of left ventricular diastolic function in primary antiphospholipid syndrome. Br Heart J 1995; 74 (05) 531-535
- 68 Nagueh SF, Smiseth OA, Appleton CP. , et al; Houston, Texas; Oslo, Norway; Phoenix, Arizona; Nashville, Tennessee; Hamilton, Ontario, Canada; Uppsala, Sweden; Ghent and Liège, Belgium; Cleveland, Ohio; Novara, Italy; Rochester, Minnesota; Bucharest, Romania; and St. Louis, Missouri. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2016; 17 (12) 1321-1360
- 69 Tufano A, Lembo M, Di Minno MN. , et al. Left ventricular diastolic abnormalities other than valvular heart disease in antiphospholipid syndrome: an echocardiographic study. Int J Cardiol 2018; 271: 366-370
- 70 Simon A, Chironi G, Levenson J. Performance of subclinical arterial disease detection as a screening test for coronary heart disease. Hypertension 2006; 48 (03) 392-396
- 71 Christodoulou C, Zain M, Bertolaccini ML. , et al. Prevalence of an abnormal ankle-brachial index in patients with antiphospholipid syndrome with pregnancy loss but without thrombosis: a controlled study. Ann Rheum Dis 2006; 65 (05) 683-684
- 72 Stalc M, Poredos P, Peternel P, Tomsic M, Sebestjen M, Kveder T. Endothelial function is impaired in patients with primary antiphospholipid syndrome. Thromb Res 2006; 118 (04) 455-461
- 73 Charakida M, Besler C, Batuca JR. , et al. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA 2009; 302 (11) 1210-1217
- 74 Andrade D, Bortolotto L, Bonfá E, Borba E. Primary antiphospholipid syndrome: absence of premature atherosclerosis in patients without traditional coronary artery disease risk factors. Lupus 2016; 25 (05) 472-478
- 75 Vlachoyiannopoulos PG, Kanellopoulos PG, Ioannidis JP, Tektonidou MG, Mastorakou I, Moutsopoulos HM. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology (Oxford) 2003; 42 (05) 645-651
- 76 Bilora F, Boccioletti V, Girolami B. , et al. Are antiphospholipid antibodies an independent risk factor for atherosclerosis?. Clin Appl Thromb Hemost 2002; 8 (02) 103-113
- 77 López-Pedrera C, Barbarroja N, Jimenez-Gomez Y, Collantes-Estevez E, Aguirre MA, Cuadrado MJ. Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: new therapeutic approaches. Rheumatology (Oxford) 2016; 55 (12) 2096-2108
- 78 Perez-Sanchez C, Barbarroja N, Messineo S. , et al. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. Ann Rheum Dis 2015; 74 (07) 1441-1449
- 79 Conti F, Spinelli FR, Alessandri C. , et al. Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: focus on β2GPI-specific T cell response. Arterioscler Thromb Vasc Biol 2014; 34 (03) 661-668
- 80 Benagiano M, Gerosa M, Romagnoli J. , et al. β2 glycoprotein I recognition drives Th1 inflammation in atherosclerotic plaques of patients with primary antiphospholipid syndrome. J Immunol 2017; 198 (07) 2640-2648
- 81 Ambrosino P, Lupoli R, Di Minno A, Iervolino S, Peluso R, Di Minno MN. Markers of cardiovascular risk in patients with antiphospholipid syndrome: a meta-analysis of literature studies. Ann Med 2014; 46 (08) 693-702
- 82 Kravvariti E, Konstantonis G, Tentolouris N, Sfikakis PP, Tektonidou MG. Carotid and femoral atherosclerosis in antiphospholipid syndrome: Equivalent risk with diabetes mellitus in a case-control study. Semin Arthritis Rheum 2018; 47 (06) 883-889
- 83 Neville C, Rauch J, Kassis J. , et al. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. Thromb Haemost 2003; 90 (01) 108-115
- 84 Di Minno MND, Emmi G, Ambrosino P. , et al. Subclinical atherosclerosis in asymptomatic carriers of persistent antiphospholipid antibodies positivity: a cross-sectional study. Int J Cardiol 2019; 274: 1-6
- 85 Locht H, Wiik A. IgG and IgM isotypes of anti-cardiolipin and anti-beta2-glycoprotein i antibodies reflect different forms of recent thrombo-embolic events. Clin Rheumatol 2006; 25 (02) 246-250
- 86 Di Minno MND, Emmi G, Ambrosino P. , et al. Impact of cardiovascular and immunologic variables on subclinical carotid atherosclerosis in subjects with anti-phospholipid antibodies. Data Brief 2018; 19: 1799-1803
- 87 O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson Jr SK. ; Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999; 340 (01) 14-22
- 88 Chambless LE, Heiss G, Folsom AR. , et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997; 146 (06) 483-494
- 89 van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation 2004; 109 (09) 1089-1094
- 90 Medina G, Casaos D, Jara LJ. , et al. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis 2003; 62 (07) 607-610
- 91 Jara LJ, Medina G, Vera-Lastra O. Systemic antiphospholipid syndrome and atherosclerosis. Clin Rev Allergy Immunol 2007; 32 (02) 172-177
- 92 Cheng CY, Zhang YX, Denas G, Du Y, Jing ZC, Pengo V. Prevalence of antiphospholipid (aPL) antibodies among patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. Intern Emerg Med 2019
- 93 Bonderman D, Wilkens H, Wakounig S. , et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 2009; 33 (02) 325-331
- 94 Pardos-Gea J, Avegliano G, Evangelista A, Vilardell M, Ordi-Ros J. Cardiac manifestations other than valvulopathy in antiphospholipid syndrome: long-time echocardiography follow-up study. Int J Rheum Dis 2015; 18 (01) 76-83
- 95 Mavrogeni SI, Sfikakis PP, Kitas GD, Kolovou G, Tektonidou MG. Cardiac involvement in antiphospholipid syndrome: the diagnostic role of noninvasive cardiac imaging. Semin Arthritis Rheum 2016; 45 (05) 611-616
- 96 Lockshin M, Tenedios F, Petri M. , et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee Consensus Report. Lupus 2003; 12 (07) 518-523
- 97 Chighizola CB, Raimondo MG, Meroni PL. Management of thrombotic antiphospholipid syndrome. Semin Thromb Hemost 2018; 44 (05) 419-426
- 98 Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med 2000; 160 (13) 2042-2048
- 99 Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I. , et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011; 20 (02) 206-218
- 100 Bertsias G, Ioannidis JPA, Boletis J. , et al; Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008; 67 (02) 195-205
- 101 Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89-118
- 102 Belizna C. Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. Autoimmun Rev 2015; 14 (04) 358-362
- 103 Nuri E, Taraborelli M, Andreoli L. , et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol Res 2017; 65 (01) 17-24
- 104 Soltész P, Szekanecz Z, Kiss E, Shoenfeld Y. Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev 2007; 6 (06) 379-386
- 105 Bundhun PK, Boodhoo KD, Long M-Y, Chen M-H. Impact of antiphospholipid syndrome and/or systemic lupus erithematosus on the long-term adverse cardiovascular outcomes in patients after percutaneous coronary intervention. A systematic review and meta-analysis. Medicine (Baltimore) 2016; 95 (12) e3200
- 106 Sciascia S, Radin M. Thrombotic antiphospholipid syndrome. Lupus 2018; 27 (1_suppl): 21-27
- 107 Cohen H, Hunt BJ, Efthymiou M. , et al; RAPS trial investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol 2016; 3 (09) e426-e436
- 108 Pengo V, Denas G, Zoppellaro G. , et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018; 132 (13) 1365-1371
- 109 Dufrost V, Risse J, Reshetnyak T. , et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev 2018; 17 (10) 1011-1021